Linguistic, Content and Face Validity of the Swedish Version of a Quality-of-Life Assessment for Children, Teenagers and Adults with Spina Bifida.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Quality of Life* ; Spinal Dysraphism*/psychology; Humans ; Adolescent ; Sweden ; Adult ; Child ; Female ; Male ; Young Adult ; Surveys and Questionnaires ; Reproducibility of Results ; Linguistics

Spina bifida includes a spectrum of different neural tube defects. Myelomeningocele is the most serious type and is associated with a risk of paralysis and sensory dysfunction below the affected level, bladder/bowel dysfunction, brain dysmorphology, and impaired health-related quality of life (HRQoL). The aim of this study was to describe the establishment of linguistic, content and face validity of the Swedish version of a Quality-of-Life Assessment for children (QUALAS-C, n = 10 items), teenagers (QUALAS-T, n = 10 items) and adults with spina bifida (QUALAS-A, n = 15 items) based on the original US English versions. The process included close collaboration with the original instrument developer and complied with international standards on patient-reported outcome measurements. The procedure includes forward translation, expert and patient/parent review and reconciliation, back translation, back translation review and cognitive debriefing interviews with 16 people with spina bifida aged 8 to 33, providing them with the possibility of evaluating the clarity, adequacy, and comprehensiveness of QUALAS-C, QUALAS-T and QUALAS-A, respectively. The interviews lasted a median of 15 min (range 8-16) for QUALAS-C, 10 min (range 9-15) for QUALAS-T and 24 min (range 9-38) for QUALAS-A. Four main issues/topics needed attention and discussion after both the forward and back translation. Following the back translation review, all issues were resolved. The patient feedback revealed recognition of the HRQoL issues included in QUALAS, and also difficulties in understanding some questions. After the patients' evaluation, four items were reworded for clarity. No study participant reported a wish to add to or remove questions from QUALAS. Hence, the Swedish versions of QUALAS became conceptually equivalent to the original US English versions and achieved linguistic, content and face validity. While empowering the voices of people with spina bifida, these results also enable their HRQoL to be properly assessed in research and clinical care in Sweden and in international studies.

Arch Phys Med Rehabil. 2005 May;86(5):979-87. (PMID: 15895345)
Arch Dis Child. 2017 May;102(5):393-400. (PMID: 27831905)
Value Health. 2005 Mar-Apr;8(2):94-104. (PMID: 15804318)
Neurourol Urodyn. 2016 Jan;35(1):8-14. (PMID: 25327455)
Int J Environ Res Public Health. 2021 Oct 13;18(20):. (PMID: 34682497)
Disabil Health J. 2018 Oct;11(4):650-654. (PMID: 29636237)
Pediatrics. 2012 Aug;130(2):181-3. (PMID: 22826577)
Urology. 2024 Feb;184:228-234. (PMID: 38159612)
J Pediatr Nurs. 2019 Nov - Dec;49:10-17. (PMID: 31421392)
Value Health. 2013 Jun;16(4):461-79. (PMID: 23796280)
Dev Med Child Neurol. 2021 Nov;63(11):1294-1301. (PMID: 33386749)
Paediatr Perinat Epidemiol. 2019 Nov;33(6):436-448. (PMID: 31637749)
J Rehabil Med. 2023 Nov 27;55:jrm18244. (PMID: 38010218)
Front Pediatr. 2020 Jul 28;8:364. (PMID: 32850521)
J Patient Rep Outcomes. 2022 May 24;6(1):53. (PMID: 35608682)
Orphanet J Rare Dis. 2017 Nov 2;12(1):171. (PMID: 29096663)
Turk J Phys Med Rehabil. 2022 Mar 01;68(1):37-45. (PMID: 35949972)
J Neurosurg Pediatr. 2022 Nov 04;31(1):3-7. (PMID: 36334287)
J Pediatr Urol. 2019 Feb;15(1):33.e1-33.e6. (PMID: 30228091)
Cent European J Urol. 2017;70(3):306-313. (PMID: 29104796)
Lancet Glob Health. 2023 Jul;11(7):e1041-e1052. (PMID: 37271162)
Childs Nerv Syst. 2017 Nov;33(11):1997-2002. (PMID: 28656385)
Clin Perinatol. 2022 Dec;49(4):835-848. (PMID: 36328602)
Int Braz J Urol. 2022 Jan-Feb;48(1):31-51. (PMID: 33861059)
Qual Life Res. 2015 Oct;24(10):2355-64. (PMID: 25863685)
Pediatr Int. 2021 Apr;63(4):423-429. (PMID: 32745355)
Acta Paediatr. 2022 Sep;111(9):1682-1694. (PMID: 35608513)
Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):181-7. (PMID: 22458619)
Childs Nerv Syst. 2016 Jan;32(1):105-10. (PMID: 26362680)
Cleft Palate Craniofac J. 2020 Jul;57(7):840-848. (PMID: 32048868)
Urology. 2016 Jan;87:178-84. (PMID: 26456744)
Pediatr Nephrol. 2024 Mar;39(3):681-697. (PMID: 37501019)
Nat Rev Dis Primers. 2015 Apr 30;1:15007. (PMID: 27189655)
Am J Public Health. 2016 Jan;106(1):e24-34. (PMID: 26562127)
Cochrane Database Syst Rev. 2021 Oct 12;10:CD011589. (PMID: 34637526)
Rev Paul Pediatr. 2021;39:e2019312. (PMID: 32876304)
Dialogues Clin Neurosci. 2014 Jun;16(2):137-45. (PMID: 25152653)
Pediatr Int. 2019 Dec;61(12):1232-1238. (PMID: 31487089)
Disabil Rehabil. 2023 Aug 2;:1-8. (PMID: 37528767)
Disabil Rehabil. 2023 Oct;45(20):3359-3365. (PMID: 36073860)
Clin Perinatol. 2022 Mar;49(1):267-277. (PMID: 35210005)
Front Pediatr. 2023 Oct 23;11:1253892. (PMID: 37936889)
Value Health. 2011 Dec;14(8):978-88. (PMID: 22152166)
PLoS One. 2024 Feb 29;19(2):e0298891. (PMID: 38422087)
J Pediatr Urol. 2013 Oct;9(5):559-66. (PMID: 23769200)
Disabil Rehabil. 2022 Sep;44(19):5479-5486. (PMID: 34106796)
J Pediatr Urol. 2018 Jun;14(3):279.e1-279.e8. (PMID: 29606358)
J Rehabil Med. 2014 Oct;46(9):891-7. (PMID: 25148270)
J Pediatr Rehabil Med. 2020;13(4):565-582. (PMID: 33325410)
J Neurosurg Pediatr. 2023 Mar 3;:1-11. (PMID: 36883627)
J Pediatr Rehabil Med. 2020;13(4):525-534. (PMID: 32986630)
Children (Basel). 2024 Feb 26;11(3):. (PMID: 38539321)
Health Qual Life Outcomes. 2006 Oct 11;4:79. (PMID: 17034633)
Childs Nerv Syst. 2020 Mar;36(3):611-616. (PMID: 31423555)
Child Care Health Dev. 2016 Sep;42(5):625-43. (PMID: 27381478)
West J Nurs Res. 2004 Apr;26(3):307-20. (PMID: 15068554)
Qual Life Res. 2021 Jul;30(7):1803-1832. (PMID: 33738710)

ALFGBG-964986 ALF Grants from the Region of Västra Götaland Sweden

Keywords: neurogenic bladder; patient-reported outcome; quality of life; rare disease; spina bifida; translation; validity

Date Created: 20240525 Date Completed: 20240525 Latest Revision: 20240527

20240527

PMC11121182

10.3390/ijerph21050624

38791838